© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Decades ago, livestock in regions across the globe faced a significant threat from liver fluke infestations. Early chemists and veterinarians observed how these parasites crippled herd health and farm yields, searching for relief beyond the basic arsenicals or outdated botanicals used in the mid-20th century. The Swiss pharmaceutical scene eventually generated triclabendazole, a benzimidazole derivative, in the late 1970s, motivated by the need for better control of Fasciola hepatica and Fasciola gigantica. The compound soon showed high activity not just against adult flukes but against immature stages—a leap ahead of older dewormers like albendazole and closantel. Multinational partnerships pushed this discovery into field trials, proving its merit in both veterinary and, eventually, human medicine. Regulatory green lights in regions troubled by fluke outbreaks cemented triclabendazole’s role, as livestock producers started to see real hope for breaking the cycle of parasite-related losses.
Triclabendazole arrives as a white to off-white crystalline powder, formulated for oral use in animals and, more recently, approved for humans. Designed for targeted parasite elimination, tablets and drenches dominate the commercial market. Maize starch, povidone, and sodium lauryl sulfate serve as common excipients, ensuring proper absorption and palatability in oral dosing. The product typically contains high-purity triclabendazole, tested rigorously before it ships out, whether heading for ranches in South America or remote clinics in Asia. Companies involved in this sector often highlight robust supply chains so farmers and healthcare workers in parasite-prone areas can count on a steady flow of effective medication.
With the formula C14H9Cl3N2OS, triclabendazole forms solid powder, barely soluble in water but showing greater solubility in organic solvents such as dimethyl sulfoxide and acetone. The melting point lands between 204°C and 208°C, signaling high thermal stability—a useful property for transport and storage under various field conditions. The molecule displays signature benzimidazole rings, three chlorine atoms, and a thioether side chain. These moieties contribute to its selectivity for fluke tubulin, while steric hindrance reduces unwanted off-target effects. Under a microscope, the powder appears dense, with a tendency to stick unless properly compounded, a detail I’ve seen trip up field operators unfamiliar with its quirks.
Each container demands clear labeling, tracking not just purity but excipient content and batch data. Pharmaceutical-grade triclabendazole typically tests above 98% purity, as per United States Pharmacopeia or European Pharmacopoeia requirements. Containers post warnings regarding storage: keep dry, shield from direct sunlight, and avoid excess heat. Labels specify dosage by species, as sheep, cattle, and humans all require sharply different amounts to achieve desired blood levels while limiting resistance risk. Manufacturers also remind users of mandated withdrawal periods for food-producing animals, protecting public health from drug residues in milk or meat. Labels in the market also display hazard pictograms, warning handlers about possible mild eye and skin irritation.
Synthesis of triclabendazole often starts with methylation of 5-chloro-2-mercaptobenzimidazole, proceeded by the stepwise introduction of additional chlorine atoms and the benzimidazole core. Key steps involve careful chlorination—using either thionyl chloride or phosphorus oxychloride solutions—and thioetherification with 2,3,6-trichloroaniline. Stringent reaction controls help prevent over-chlorination, safeguarding yield and purity. Crystallization and filtration remove impurities, followed by drying under vacuum. Labs ensure tight environmental controls throughout, as even trace moisture can affect finished batch quality. Technicians follow detailed protocols for washing glassware and monitoring reaction temperatures, which keeps product quality high—something that rigorous users in the field have come to expect.
Triclabendazole’s structure resists many mild oxidizers and acids, meaning it remains stable in a range of medicated feed formulations. Chemical modifications often aim at improving bioavailability or tweaking selectivity for specific parasite enzymes, focusing mostly on the benzimidazole core. Med-chem researchers sometimes swap out chlorine atoms for other halogens or extend the thioether side chain in the hunt for an even broader spectrum. Early research into prodrug strategies—attaching hydrophilic groups for improved gastrointestinal absorption—has shown promise in small animal models but not yet seen full clinical translation. Laboratories avoid aggressive hydrolysis or prolonged UV exposure, which can break molecular bonds and reduce the activity.
You’ll find triclabendazole sold under trade names like Fasinex, Endex, and Trivantel, depending on the region or to meet regulatory preferences. On the technical side, common synonyms pop up in scientific literature—TCBZ, 6-chloro-2-(3,5-dichlorophenoxy)-1H-benzimidazole. Bulk suppliers might list it by its IUPAC name or CAS number for procurement specialists. Knowing the local product name helps avoid confusion, especially in fieldwork or global research collaborations that span multiple continents and regulatory regimes.
Handlers receive clear safety advice: wear gloves and use goggles to block accidental contact, since dust can irritate the skin or eyes. In production plants, local exhaust ventilation and dust-control systems help workers avoid inhaling fine particles. Safety sheets also lay out steps for accidental spills—contain dust with damp cloths, dispose in properly marked biohazard bags, and alert environmental health teams, especially near water sources. Disposal teams follow both WHO and regional guidelines for destruction of expired or contaminated product. Farms routinely train personnel to prevent misuse, as triclabendazole overuse can drive resistance. Labs mandate calibration checks on balances and pH meters, tying into broader quality assurance protocols.
Triclabendazole changed the game for livestock producers in fluke-prone grasslands. Its broad activity against early and late liver fluke stages underscores why veterinarians reached for it over competing products. Small family operations to major cattle ranches integrated drench or bolus regimens, lifting herd health and economic returns. In the last decade, regulatory bodies in countries like Egypt, Vietnam, or Peru approved its use for human fascioliasis, giving rural clinics a needed tool against stubborn outbreaks. Hospitals and NGOs on the front lines deworm children and adults with single or divided doses, tracking patient outcomes and flagging resistance clusters as needed.
With growing resistance seen on ranch lands in South America and Central Europe, research programs ramped up. Investigators map genetic changes in liver flukes exposed to years of triclabendazole, looking for mutations conferring reduced drug binding and suggesting alternative treatment protocols. Laboratories screen structural analogues of triclabendazole, using high-throughput platforms to hunt for candidates keeping activity against resistant fluke strains. Combination therapies—with agents like oxyclozanide or new enzyme inhibitors—get tested for practical dose schedules that keep costs reasonable for struggling farmers and public health clinics. In-house pilot projects sometimes run small field trials, sampling fecal eggs pre- and post-treatment, making sure proposals work outside the lab.
Laboratories run animal studies with rats, sheep, and fish to check for accidental impacts outside the target pest. Acute toxicity sits low at recommended doses, though caution rises in pregnant or lactating animals, prompting conservative label rates. In early trials, rare liver enzyme spikes and gastrointestinal upset occurred in some treated patients, but extensive epidemiologic follow-ups found no major concerns in communities with large-scale use. Environmental studies trace drug metabolites in water runoff, tracking risks to aquatic life; findings so far show minimal harm at environmental concentrations, though advocates continue pressing for careful monitoring. Repeated dosing and sustained exposure studies guide current recommendations for withdrawal times and interval treatments.
Fluke management isn’t going away soon, as grazing habits, climate change, and water management keep reshaping parasite risk. Triclabendazole’s durability—seen in its sustained activity across many regions—remains a core advantage, but reliance breeds risk of resistance. Research groups look toward smarter delivery, from controlled-release formulations to drone-assisted dosing, cutting labor costs and tightening accuracy. On the public health front, food safety and anti-resistance surveillance increase, requiring fast detection of residues and early warning systems for reduced drug sensitivity. Global organizations urge stewardship programs pairing triclabendazole with integrated farm management, rotating pasture, and diversifying treatment to slow the spread of resistance. Collaborative efforts between academia, pharma, and grassroots ag groups drive innovation—ensuring that triclabendazole keeps its place in the toolkit, but never as the sole line of defense.
Triclabendazole doesn’t come up in casual conversation. Maybe it should. In my years around public health, I’ve watched how one small pill can turn fear and uncertainty into hope, especially in places where few people know what “liver flukes” are until they start to get sick. This drug treats parasitic infections, mostly from freshwater snails, that keep millions of people in parts of Asia, Africa, the Middle East, and South America from living their best lives. The main villains are two parasitic flatworms: Fasciola hepatica and Fasciola gigantica.
Someone living near slow-moving rivers or lakes often picks up this infection through contaminated water or by eating plants washed in it. They won’t always notice at first. Then come fevers, stomach pain, and even damage to their liver and bile ducts. Left untreated, fascioliasis (the disease’s name) saps energy and upends whole households. The problem spans continents but hides in the shadows, too often ignored by governments and pharmaceutical companies chasing bigger problems with better publicity.
Doctors have struggled to treat fascioliasis with anything but triclabendazole. Other drugs usually don’t work. Triclabendazole gets right to the adult and immature parasites, clearing infections from the liver and helping people return to work and school. The World Health Organization lists this drug as essential. That doesn’t happen unless it saves lives, not just in theory but in villages, refugee camps, homes with dirt floors, and towns battered by floods. I remember speaking with a doctor in Bolivia who described how triclabendazole turned desperate cases—kids who stopped eating, farmers too weak to work—into recovery stories.
Still, good drugs don’t always reach the right hands. Supplies run short. Prices climb. People travel long distances for a diagnosis, only to face empty shelves or fakes. The story doesn’t end there. Overuse and misuse can breed resistance, turning last-resort medicines unreliable. I’ve seen frustrated families share leftover pills or buy black market versions, risking treatment failure and side effects.
Access stretches beyond inventing new medicines. It means honest supply chains, government support, and public health outreach—especially education about safe water and hygiene. Pharmaceutical companies need fair pricing and stronger relationships with local clinics. Doctors deserve better support making tough calls in low-resource clinics. Health ministries who spot resistance patterns early can help adapt strategies before triclabendazole loses power for good.
It’s easy for the issue to slip out of sight from the comfort of a city untouched by liver flukes. On the ground, one medicine makes a world of difference. Continued research, investment in cleaner water, and smarter distribution of essential drugs like triclabendazole do more than fight parasites—they offer dignity and hope where it’s needed most.
Anyone who’s dealt with fascioliasis, a liver fluke infection, remembers the discomfort. The medicine widely trusted is triclabendazole, which has a track record that gives families and doctors some peace of mind. Making the most out of this treatment hinges on taking it the right way—and even little missteps can stretch out recovery.
Triclabendazole shows up as a tablet. Adults and kids over six years get the same dose—10mg per kilogram of body weight, ideally swallowed whole with food. This isn’t just any advice, but a practical necessity: the medicine absorbs better alongside some grease from a meal. Skipping food means less medicine gets into the system and that could mean lingering parasites. For tough cases, the same dose is repeated after 12 hours. It’s a simple routine, but I’ve watched patients stumble when they tried to cut corners, like taking it on an empty stomach or splitting up the dose hours later than recommended.
With a family member once wrestling with persistent symptoms months after poor adherence, I’ve learned food isn’t just a side note here. Studies show that fatty foods can boost triclabendazole absorption two to three times. This effect lowers the odds of treatment failure. A heavy breakfast makes the tablet’s bitter taste easier to swallow, and keeps stomach upset at bay—a pointed reminder that directions on the label really do matter.
No drug is free from risks. After starting triclabendazole, patients may feel mild nausea, headaches, or stomach cramps. These symptoms usually pass quickly, often disappearing after a day. Every so often, allergic reactions occur—rash, swelling—though I’ve only seen one such case in my practice. The key thing: never tough it out alone. Anyone seeing trouble after a dose should return to their prescriber and talk things through.
People get into trouble with medicines more often when instructions aren’t clear. I’ve witnessed confusion among patients who couldn’t track dose timing, especially for children. Written plans help. Doctors should explain how to track doses and stress the value of full adherence. Pharmacists can provide reminders for families juggling multiple medications. Patients sometimes ask about splitting tablets to stretch the medicine out, but this leads straight to dosing mistakes. The tablets aren’t scored for splitting. Swallow whole or let a pharmacist show how to crush and mix with soft food for young kids.
Not every pharmacy stocks triclabendazole, particularly in rural spots. This leaves some families scrambling, which raises the risk that a course ends up late or not started at all. Medical providers can help by checking local supply before prescribing, or by linking the patient to hospitals known to keep it on hand. Non-profit efforts like WHO’s control programs have improved access in the last decade, but local gaps remain.
Treating parasitic infections takes clear instructions and diligence. Triclabendazole shows its true value only when taken exactly as directed. Eating before each dose, using the right timing, and reporting any problems keeps complications low. Real-life experience backs up what the research says—patients who follow these steps get better, faster, and with fewer bumps along the way.
Triclabendazole fights parasitic infections like fascioliasis, which often hit people living in or working near freshwater areas. If you’ve been prescribed this drug, you’re probably more focused on its power to clear parasites than anything else. My first experience with anti-parasitic medicines opened my eyes to the balance between curing a tough infection and dealing with possible side effects. Truth is, even drugs that do the job smoothly for most can affect each person differently.
Many who take triclabendazole notice mild discomfort rather than anything severe. Digestive issues seem to top the list; some users report stomach pain, nausea, or a lingering metallic taste in the mouth. It’s not rare to feel queasy or lose your appetite—a reason many doctors suggest smaller meals during treatment. The body, already fighting off parasites, can protest once the medication starts working.
Others experience headaches or tiredness after swallowing the tablets. These effects often pass on their own, but it pays to be patient and keep track of how you feel throughout the course. I’ve learned not to brush off even mild symptoms. Jotting down any new issues helps when talking to your doctor.
People sometimes react more strongly, especially if they tend to patchy skin or have a history of allergies. Itching or rashes may show up—signals that you should contact your healthcare provider right away. Swelling of lips, face, or throat can get serious quickly and always warrants immediate help. Healthcare professionals emphasize not trying to ride out severe symptoms, as prompt treatment matters.
Many patients need liver tests before and after using triclabendazole. This medicine can, on occasion, bump up your liver enzymes or cause yellowing of the skin and eyes (jaundice). I once heard from a pharmacist friend about a cluster of cases where people didn’t realize their fatigue tied back to the drug’s liver effects. Blood tests catch problems before they snowball—any unexplained drowsiness or itchiness may need a doctor’s review.
People sometimes shrug off mild side effects, focusing on getting rid of the parasite. My advice, after hearing both medical experts and folks in local support groups, is to stay in touch with your health team throughout the process. Tell your doctor about every medicine or supplement you’re taking, as mixing drugs can trigger reactions you don’t expect.
Not everyone will run into problems, but recognizing side effects early speeds up recovery and helps avoid complications. Access to accurate, trustworthy information about drugs like triclabendazole helps patients make smarter choices. For anyone with pre-existing health conditions or concerns about their liver, regular follow-up visits play a big role in staying safe.
As with any medication, talking honestly about what’s happening in your body leads to better treatment. Side effects can crop up unexpectedly but managing them means remaining alert and involved in your own care. Both patients and healthcare workers benefit from open, ongoing conversations about medicines like triclabendazole, since being informed protects everyone’s health in the long run.
Many folks looking for answers about Triclabendazole worry about their health and cost. After all, Triclabendazole treats serious parasitic infections—the sort most people pick up from animals, unclean water, or on travels in certain regions. Young children, elderly people, or those with weak immune systems feel these infections the hardest. So when symptoms hit, time matters. I remember seeing how stressed some families felt while waiting for a clear diagnosis and that green light from the doctor to get treatment started. That’s a long stretch for anyone watching someone they love suffer.
Triclabendazole targets a specific kind of flatworm infection, especially fascioliasis, which health experts call a neglected tropical disease. The medicine works well, but it doesn’t cover all types of worms or every worm-related illness. A precise diagnosis makes all the difference. Doctors don’t just hand out scripts; they confirm infection through stool tests or scans. That keeps other illnesses from getting mixed up with liver fluke—mistakes can bring other health problems. Using Triclabendazole outside of medical advice, whether from buying online or from stores in countries with looser controls, risks missing the real cause of illness or even allergic reactions.
In many nations, Triclabendazole counts as a prescription medicine. In the United States, the FDA gave nod to its use in 2019—but only after a doctor’s script. You won’t find it behind the pharmacy counter. In places like the UK, doctors follow a similar path. Health authorities want people treated fast but also safely. Their goal is to steer clear of dangerous misuse and watch out for groups like pregnant women or people on multiple medicines, since drug interactions sometimes surprise even the most careful patient.
Online forums fill up with stories of travelers or expats tracking down antiparasitic drugs overseas, hoping to avoid doctor visits or save money. I’ve watched some think they’re saving a step, but later deal with lasting stomach pain, allergic reactions, or worse—a misdiagnosed illness with no end in sight. Black-market or unregulated pills can be fake or contaminated. They also cause issues with drug resistance in the community, making future infections even harder to treat.
Access still creates big hurdles, especially outside major cities or in remote communities. Triclabendazole doesn’t appear in every pharmacy. Some regions feel left out, waiting for supplies to show up. That’s a spot where stronger partnerships between drug makers, health agencies, and non-profits can change lives. Local health workers trained to spot warning signs, and telemedicine for prescription review, can cut waiting times and offer trusted guidance. No one wants to get sick, then sit for days while the right tablets gather dust on a distant shelf.
Doctors and pharmacists don’t block the path to medicine to slow things down—they want to keep patients safe. Each step in this process, from symptoms to diagnosis to picking up a prescription, exists for a reason. For people living or working in countries where these infections pop up more often, clear education, early diagnosis, and steady supply chains for medicines create a shield against serious complications. We all win when medicine stays safe, effective, and in the right hands.
Triclabendazole came into the spotlight as a weapon against liver fluke infections, a health problem that mostly shows up in parts of Asia, Africa, and South America. A lot of families rely on their local doctors and the World Health Organization (WHO) to offer real solutions because liver fluke infections can sneak up on kids and adults living near freshwater sources. So, the use of Triclabendazole in groups seen as more vulnerable—children and pregnant women—matters deeply on two levels: safety and the chance to actually get rid of the parasite for good.
Children often pick up foodborne and waterborne infections because their outdoor play puts them in contact with places where liver flukes live. Triclabendazole stands out in recent years for being both potent and straightforward. Instead of requiring weeks of medication, doctors prescribe just one or two doses. That kind of simplicity supports families in rural areas, making life easier for parents juggling work and home.
Experts at the WHO recommend Triclabendazole for children ages six and older—when prescribed at the right dose and under medical guidance. In countries where riverbank farming and water chores are day-to-day, kids face greater risk for exposure. Leaving these infections untreated long-term brings serious consequences, from organ damage to missed school days. Side effects show up for some kids—stomach upset, headache, skin changes—but health agencies keep a close eye to keep them rare.
Pregnancy changes the way the body reacts to many medicines. In most areas, doctors still show special caution before reaching for Triclabendazole during pregnancy, especially within the first three months. Animal studies hint at risks, and human studies just don’t bring enough solid answers yet. When the mother faces life-threatening infection, and the benefits clearly outweigh risks, treatment might be considered, but the choices grow tough. Families and care teams weigh options closely, often waiting until after the early weeks unless infection proves severe.
The safety question continues to grow in importance as more global health groups push for access to parasite treatments. Agencies like the U.S. Centers for Disease Control and Prevention (CDC) echo cautious advice, encouraging treatment for women after pregnancy when possible and before getting pregnant, especially in places where infections happen often.
People often assume that a medicine that works for adults automatically works for children or pregnant women. Personal experience as a healthcare provider serving families in rural settings reminds me that each child and mother faces a unique context. Clear communication—between patient, doctor, and community health worker—helps make the best use of each medicine. More research still has to fill the gaps, especially for pregnant women.
Meanwhile, using diagnosed care, support from experienced providers, and honest discussions about side effects and benefits forms the right foundation. It helps families make informed decisions, boosts trust in the healthcare system, and, most importantly, saves lives where it counts the most. Governments and global drug approval authorities keep track of each case, monitor the outcomes, and share real-world results. As access to Triclabendazole widens, those steps help protect the most vulnerable while chipping away at the global burden of parasite disease.
| Names | |
| Preferred IUPAC name | 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole |
| Other names |
Fasinex Triclam Endex Triclaben Tricide |
| Pronunciation | /traɪˌklæb.ɛnˈdəʊ.zɒl/ |
| Identifiers | |
| CAS Number | [68786-66-3] |
| 3D model (JSmol) | `3DModel:JSmol:C1=CC=C2C(=C1)C(=NC(=O)S2)N(C3=CC=CC=C3)C4=CC=C(C=C4)Cl` |
| Beilstein Reference | 91494 |
| ChEBI | CHEBI:9646 |
| ChEMBL | CHEMBL1412 |
| ChemSpider | 2156 |
| DrugBank | DB00857 |
| ECHA InfoCard | 03e50fd9-c2b2-4cae-8e6d-b237b7e6d2ce |
| EC Number | 6.3.1.9 |
| Gmelin Reference | 821963 |
| KEGG | D08668 |
| MeSH | D016527 |
| PubChem CID | 643173 |
| RTECS number | XN6476000 |
| UNII | 3T2J0F7G1U |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C14H9Cl3N2OS |
| Molar mass | 359.91 g/mol |
| Appearance | White to almost white crystalline powder. |
| Odor | Odorless |
| Density | 1.504 g/cm3 |
| Solubility in water | Very slightly soluble in water |
| log P | 2.87 |
| Vapor pressure | 0.000000000432 mmHg at 25°C |
| Acidity (pKa) | 12.57 |
| Basicity (pKb) | 2.96 |
| Refractive index (nD) | 1.614 |
| Dipole moment | 2.72 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Triclabendazole standard molar entropy (S⦵298): 0.533 kJ·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -119.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5767 kJ/mol |
| Pharmacology | |
| ATC code | P02BX02 |
| Hazards | |
| Main hazards | May cause damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P264, P270, P273, P280, P305+P351+P338, P337+P313, P308+P313 |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 1, Instability: 0, Special: - |
| Lethal dose or concentration | LD50 oral rat: 2020 mg/kg |
| LD50 (median dose) | LD50 (median dose): Oral, rat: 5000 mg/kg |
| NIOSH | PB6475000 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 10 mg/kg body weight as a single dose |
| IDLH (Immediate danger) | No IDLH established |
| Related compounds | |
| Related compounds |
Albendazole Fenbendazole Mebendazole Oxfendazole Oxibendazole Thiabendazole |
